Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
link
Tags
medicine
23andme
anne wojcicki
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
biotech
bluebird bio
boston
boston blog main
boston top stories
business
cancer
clinical trials
dfj
dna
draper fisher jurveston
duchenne muscular dystrophy
dyne therapeutics
facioscapulohumeral muscular dystrophy
ge ventures
gear
gene therapy
genetic testing
genetics
health
jobs
joshua brumm
kaleido biosciences
layoffs
life sciences
mayo clinic ventures
muscular dystrophy
myotonic dystrophy type 1
national blog main
national top stories
new york blog main
occupational safety and health
pathology
What
expected
5
×
genetic
5
×
gene
having
patients
rare
beef
bills
disease
doctors
genome
instead
marker
market
maybe
medical
person
sequenced
symptoms
test
ability
acknowledging
ago
amid
andme
billion
biotechs
bring
businesses
cancer
car
cell
cellular
chain
clinic
clinical
companies
considering
data
delivery
Language
unset
Current search:
expected
×
genetic
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@engadget.com
4 years ago
23andMe lays off 100 workers amid shrinking demand for DNA tests
@WIRED
6 years ago
When doctors genome sequenced 50 test patients, they expected to find *maybe* one person with a genetic disease marker. Instead, they found 11.
@WIRED
6 years ago
When doctors genome sequenced 50 test patients, they expected to find *maybe* one person with a genetic disease marker. Instead, they found 11.
@techcrunch.com
6 years ago
GE and the Mayo Clinic back software to bring cancer-fighting gene therapies to market
